Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | PI4KA | P42356 | 2/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020656 | 1.00 | ADORA2A (0.65) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14327782 | 1.00 | ADORA2A (0.65) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17081750 | 1.00 | ADORA2A (0.65) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13064103 | 1.00 | ADORA2A (0.65) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13770319 | 0.91 | ADORA2A (0.59) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31704107 | 0.88 | ADORA3 (0.63) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29936486 | 0.88 | PRMT5 (0.69) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL8626036 | 0.88 | PRMT5 (0.69) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14586086 | 0.87 | ADORA2A (0.49) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4658300 | 0.87 | ADORA3 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716742-A2 | COMPOSITIONS AND METHODS TO MODULATE TRANSPOSABLE ELEMENTS GOVERNING CELL-STATE TRANSITIONS | Haya Therapeutics SA (CH) | 2026-04-01 | — | — | EP | disclosed |
| WO-2025068766-A2 | COMPOSITIONS AND METHODS TO MODULATE IDIOPATHIC PULMONARY FIBROTIC ASSOCIATED LONG NONCODING RNAS | HAYA THERAPEUTICS SA (CH) | 2025-04-03 | — | — | WO | disclosed |
| EP-4514969-A1 | COMPOSITIONS AND METHODS OF MODULATING LONG NONCODING TRANSCRIPTS ASSOCIATED WITH ARDS INDUCED PULMONARY FIBROSIS | Haya Therapeutics SA (CH) | 2025-03-05 | — | — | EP | disclosed |
| US-20250051776-A1 | COMPOSITIONS AND METHODS OF MODULATING LONG NONCODING TRANSCRIPTS ASSOCIATED WITH ARDS INDUCED PULMONARY FIBROSIS | HAYA THERAPEUTICS SA (CH) | 2025-02-13 | — | — | US | disclosed |
| WO-2024241091-A2 | COMPOSITIONS AND METHODS TO MODULATE TRANSPOSABLE ELEMENTS GOVERNING CELL-STATE TRANSITIONS | HAYA THERAPEUTICS SA (CH) | 2024-11-28 | — | — | WO | disclosed |
| WO-2023209437-A1 | COMPOSITIONS AND METHODS OF MODULATING LONG NONCODING TRANSCRIPTS ASSOCIATED WITH ARDS INDUCED PULMONARY FIBROSIS | HAYA THERAPEUTICS SA (CH) | 2023-11-02 | — | — | WO | disclosed |
| US-9133230-B2 | Hydrazone derivatives having potent antitumor activity toward multi-drug resistant tumor cells | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2015-09-15 | — | — | US | disclosed |
| EP-1868628-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF POXVIRUS INFECTIONS | CHIMERIX INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8642577-B2 | Compounds, compositions and methods for the treatment of poxvirus infections | CHIMERIX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120329747-A1 | NOVEL HYDRAZONE DERIVATIVES HAVING POTENT ANTITUMOR ACTIVITY TOWARD MULTI-DRUG RESISTANT TUMOR CELLS | THE TRUSTEES OF INDIANA UNIVERSITY | 2012-12-27 | — | — | US | disclosed |
| WO-2011005595-A2 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2007-01-04 | — | — | US | disclosed |
| EP-1165585-A1 | CLEAVAGE OF NUCLEIC ACID FROM SOLID SUPPORTS | Goldsborough, Andrew (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058329-A1 | CLEAVAGE OF NUCLEIC ACID FROM SOLID SUPPORTS | GOLDSBOROUGH, ANDREW (FR) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | IFNG, POLI, STING1 | ADORA2A 2217/4885PI4KA 189/4885PI4K2B 318/4885 |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | ADORA2A 877/4885PI4KA 1931/4885PI4K2B 1836/4885 |
| US-20120329747-A1 | NOVEL HYDRAZONE DERIVATIVES HAVING POTENT ANTITUMOR ACTIVITY TOWARD MULTI-DRUG RESISTANT TUMOR CELLS | ABCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC5 | ADORA2A 3899/4885PI4KA 1579/4885PI4K2B 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.